Home › Mesothelioma › NCT06037941
Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
Breathprinting (E-Nose) Technology to Measure Response to Treatment of Malignant Pleural Mesothelioma (MPM) Through MPM-Specific Volatile Organic Compounds Detected in Exhalates
Who can join
Ages 30 to 85 · All sexes
Full eligibility criteria
Inclusion Criteria: * Aged 30-85 years * No history of thoracic cancer or extrathoracic cancer potentially involving pleural metastases (i.e., breast, gastric, colon, or pancreas cancer) * Recent diagnosis of MPM * Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study, and signed standard surgical consent for surgical resection Exclusion Criteria: * Aged \<30 or \>85 years at the first outpatient visit * History of thoracic or extrathoracic cancer that puts the subject at risk for pleural or pulmonary metastases
About the study
The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood.
What is being tested
- E-Nose testing (diagnostic test)
- Research blood (diagnostic test)
Sponsor: Memorial Sloan Kettering Cancer Center · Participants: 20 · Started: Sep 8, 2023
Contact the study team
- Gaetano Rocco, MD · Phone: 212-639-3478
- David Jones, MD · Phone: 212-639-6428
Official record on ClinicalTrials.gov — NCT06037941
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.